Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, et al. Patterns of treatment failure in anaplastic thyroid carcinoma. Thyroid. 2017;27(5):672–81. https://doi.org/10.1089/thy.2016.0395.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin B, Ma H, Ma M, Zhang Z, Sun Z, Hsieh IY, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J translational Res. 2019;11(9):5888–96.

Google Scholar 

Huang NS, Wei WJ, Xiang J, Chen JY, Guan Q, Lu ZW, et al. The efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced thyroid cancer: a single-arm phase II clinical trial. Thyroid®. 2021;31(12):1808–13. https://doi.org/10.1089/thy.2021.0307.

Article  CAS  PubMed  Google Scholar 

Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid®. 2019;29(8):1036–43. https://doi.org/10.1089/thy.2019.0133.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamazaki H, Sugino K, Katoh R, Matsuzu K, Masaki C, Akaishi J, et al. Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma. Cancer Med. 2023;12(3):3027–35. https://doi.org/10.1002/cam4.5219.

Article  CAS  PubMed  Google Scholar 

Abdel-Rahman O, Ghosh S. Changes in the outcomes of patients with anaplastic thyroid carcinoma over the past two decades. Endocrine. 2024;84(1):155–9. https://doi.org/10.1007/s12020-023-03556-8.

Article  CAS  PubMed  Google Scholar 

Landa I, Cabanillas ME. Genomic alterations in thyroid cancer: biological and clinical insights. Nat Rev Endocrinol. 2024;20(2):93–110. https://doi.org/10.1038/s41574-023-00920-6.

Article  PubMed  Google Scholar 

Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, et al. Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid®. 2020;30(10):1505–17. https://doi.org/10.1089/thy.2020.0086.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016;23(3):R143-55. https://doi.org/10.1530/erc-15-0533.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022;29(5):946–60. https://doi.org/10.1038/s41418-022-00988-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184–99. https://doi.org/10.1038/nrc3431.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. https://doi.org/10.1186/s12943-023-01827-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seger R. Special issue: MAPK signaling cascades in human health and diseases. Int J Mol Sci. 2024. https://doi.org/10.3390/ijms252011226.

Article  PubMed  PubMed Central  Google Scholar 

Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875–85. https://doi.org/10.1038/nrm1498.

Article  CAS  PubMed  Google Scholar 

Liu R, Zhang T, Zhu G, Xing M. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nat Commun. 2018;9(1):579. https://doi.org/10.1038/s41467-018-03033-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–62. https://doi.org/10.1038/nrc2664.

Article  CAS  PubMed  Google Scholar 

Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid. 2010;20(7):697–706. https://doi.org/10.1089/thy.2010.1646.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017;13(11):644–60. https://doi.org/10.1038/nrendo.2017.76.

Article  CAS  PubMed  Google Scholar 

Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–66. https://doi.org/10.1158/0008-5472.Can-18-3962.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yin H, Tang Y, Guo Y, Wen S. Immune microenvironment of thyroid cancer. J Cancer. 2020;11(16):4884–96. https://doi.org/10.7150/jca.44506.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lv J, Liu C, Chen FK, Feng ZP, Jia L, Liu PJ, et al. M2‑like tumour‑associated macrophage‑secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway. Mol Med Rep. 2021. https://doi.org/10.3892/mmr.2021.12249.

Article  PubMed  PubMed Central  Google Scholar 

Caillou B, Talbot M, Weyemi U, Pioche-Durieu C, Al Ghuzlan A, Bidart JM, et al. Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One. 2011;6(7):e22567. https://doi.org/10.1371/journal.pone.0022567.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bi J, Tian Z. NK cell dysfunction and checkpoint immunotherapy. Front Immunol. 2019;10:1999. https://doi.org/10.3389/fimmu.2019.01999.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pan Z, Tan Z, Xu N, Yao Z, Zheng C, Shang J, et al. Integrative proteogenomic characterization reveals therapeutic targets in poorly differentiated and anaplastic thyroid cancers. Nat Commun. 2025;16(1):3601. https://doi.org/10.1038/s41467-025-58910-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cristinziano L, Modestino L, Loffredo S, Varricchi G, Braile M, Ferrara AL, et al. Anaplastic thyroid cancer cells induce the release of mitochondrial extracellular DNA traps by viable neutrophils. J Immunol. 1950;204(5):1362–72. https://doi.org/10.4049/jimmunol.1900543.

Article  CAS  Google Scholar 

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. https://doi.org/10.1038/nrc3239.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suzuki S, Shibata M, Gonda K, Kanke Y, Ashizawa M, Ujiie D, et al. Immunosuppression involving increased myeloid-derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer. Mol Clin Oncol. 2013;1(6):959–64. https://doi.org/10.3892/mco.2013.170.

Article  CAS  PubMed  PubMed Central